Stockscreener 앱 받기
0.9779
2.21%
-0.0221
시간 외 거래:
.97
-0.0079
-0.81%
전일 마감가:
$1.00
열려 있는:
$0.99
하루 거래량:
927.36K
Relative Volume:
0.38
시가총액:
$5.71M
수익:
$34.07M
순이익/손실:
$-20.13M
주가수익비율:
-0.0571
EPS:
-17.1162
순현금흐름:
$-24.90M
1주 성능:
+11.63%
1개월 성능:
+1.86%
6개월 성능:
-43.15%
1년 성능:
-78.02%
1일 변동 폭
$0.91
$1.06
1주일 범위
$0.7946
$2.22
52주 변동 폭
$0.61
$4.39
Biofrontera Inc Stock (BFRI) Company Profile
명칭
Biofrontera Inc
전화
781-245-1325
주소
120 PRESIDENTIAL WAY,, WOBURN
Biofrontera Inc 주식(BFRI)의 최신 뉴스
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC - TipRanks
Biofrontera Inc. Announces Highly Significant Results In - GlobeNewswire
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Yahoo Finance
Biofrontera locks phase 3 sBCC study database for analysis By Investing.com - Investing.com Australia
Biofrontera locks phase 3 sBCC study database for analysis - Investing.com India
Biofrontera Inc. Announces Database Lock Of Phase 3 Study - GlobeNewswire
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - StockTitan
BFRI’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Mass. Biotech Receives FDA Approval - Streetwise Reports
Roth/MKM sets Biofrontera target at $16, reiterates buy rating By Investing.com - Investing.com South Africa
Roth/MKM sets Biofrontera target at $16, reiterates buy rating - Investing.com India
What was Biofrontera Inc (BFRI)’s performance in the last session? - US Post News
Biofrontera says FDA approves use of up to 3 tubes of Ameluz topical gel 10% - TipRanks
Biofrontera’s Ameluz Gel FDA Approval for Higher Dosage - TipRanks
FDA approves expanded use of Biofrontera's Ameluz for AK - Investing.com
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - The Manila Times
FDA approves expanded use of Biofrontera's Ameluz for AK By Investing.com - Investing.com UK
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s - GlobeNewswire
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment - StockTitan
BFRI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Ratio Examination: Biofrontera Inc (BFRI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Tilray Brands (TLRY) Stock Surges Amidst Market Volatility - GuruFocus.com
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
Biofrontera Second Quarter 2024 Earnings: €0.023 loss per share (vs €0.12 profit in 2Q 2023) - Yahoo Finance
Five PDUFA dates on FDA’s October agenda - BioCentury
Photodynamic Therapy Market Share, Trends, Size, Major Players And Forecast To 2033 - WhaTech
Biotech Stocks Facing FDA Decision In October 2024 - Nasdaq
Biofrontera Inc.'s (NASDAQ:BFRI) Shares Leap 25% Yet They're Still Not Telling The Full Story - Simply Wall St
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference - StockTitan
Taking on analysts’ expectations and winning: Biofrontera Inc (BFRI) - SETE News
Trading Day Triumph: Biofrontera Inc (BFRI) Ends at 1.28, a 0.00 Surge/Plunge - The Dwinnex
A stock that deserves closer examination: Biofrontera Inc (BFRI) - US Post News
Leidos Holdings, Inc. (NYSE:LDOS) Shares Sold by Tredje AP fonden - Defense World
Market Insight: Biofrontera Inc (BFRI)’s Notable Gain, Closing at 1.29 - The Dwinnex
Taking the lead: Biofrontera Inc (BFRI) - SETE News
Biofrontera Inc (BFRI) Stock: From Low to High in 52 Weeks - The InvestChronicle
Biofrontera Inc (BFRI) is an excellent investment, but the stock is overvalued/undervalued right now - US Post News
Biofrontera Inc (BFRI) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Biofrontera Inc (BFRI) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Biofrontera Inc (BFRI)’s results reveal risk - US Post News
Louisiana State Employees Retirement System Acquires 700 Shares of HNI Co. (NYSE:HNI) - Defense World
A SPAC II Acquisition Corp. (NASDAQ:ASCB) Sees Large Decrease in Short Interest - Defense World
Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Biofrontera (NASDAQ:BFRI) Stock Rating Reaffirmed by Benchmark - Defense World
Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Biofrontera Inc (BFRI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.88%
0.42%
자본화:
|
볼륨(24시간):